Company / SG&A per Share
Xeris Biopharma Holdings, Inc. SG&A per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.22
FY2025
5-year range
$1.01 / $2.95
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
#108 of 210
Health Care
What the data says
At $1.22, Xeris Biopharma Holdings, Inc.'s sg&a per share ranks #103 of 210 in the Health Care sector. SG&A per Share has increased for 3 consecutive years, from $1.01 in FY2022 to $1.22 in FY2025.
Based on SEC 10-K filings.
1.22 in FY2025 with a 5-year CAGR of -6.7%.
Increased from $1.07 to $1.22 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Sector benchmark
#103 of 210 in Health CareTop 49% of 210This company $1.22 Sector average $40.75
▼
-97.0% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 3.1% year-over-year.
- Ranks #108 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.22 | +3.1% |
| FY2024 | $1.18 | +10.4% |
| FY2023 | $1.07 | +6.5% |
| FY2022 | $1.01 | -65.9% |
| FY2021 | $2.95 | +70.5% |
| FY2020 | $1.73 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026